May 10 |
Cassava swings to Q1 profit as more patients finish simufilam phase 3 trials
|
May 10 |
Cassava Sciences GAAP EPS of -$0.43 beats by $0.03
|
May 10 |
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
|
May 8 |
Cassava Sciences raises over $125M from warrant distribution
|
May 8 |
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
|
May 1 |
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
|
Apr 30 |
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
|
Apr 15 |
Redemption Date Announced for Warrants
|
Mar 25 |
Cassava Sciences: New Year, Same Game Of Smoke And Mirrors
|
Mar 25 |
Cassava Alzheimer's candidate simufilam clears phase 3 safety review
|